Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation
© Howard et al; licensee BioMed Central Ltd. 2007
Received: 04 December 2006
Accepted: 30 July 2007
Published: 30 July 2007
Skip to main content
© Howard et al; licensee BioMed Central Ltd. 2007
Received: 04 December 2006
Accepted: 30 July 2007
Published: 30 July 2007
Protein aggregation is a hallmark of several neurodegenerative diseases including Huntington's disease and Parkinson's disease. Proteins containing long, homopolymeric stretches of glutamine are especially prone to form aggregates. It has long been known that the small protein modifier, ubiquitin, localizes to these aggregates. In this report, nematode and cell culture models for polyglutamine aggregation are used to investigate the role of the ubiquitin pathway in protein aggregation.
Ubiquitin conjugating enzymes (Ubc's) were identified that affect polyglutamine aggregates in C. elegans. Specifically, RNAi knockdown of ubc-2 or ubc-22 causes a significant increase in the size of aggregates as well as a reduction in aggregate number. In contrast, RNAi of ubc-1, ubc-13, or uev-1 leads to a reduction of aggregate size and eliminates ubiquitin and proteasome localization to aggregates. In cultured human cells, shRNA knockdown of human homologs of these Ubc's (Ube2A, UbcH5b, and E2-25K) causes similar effects indicating a conserved role for ubiquitination in polyglutamine protein aggregation.
Results of knockdown of different Ubc enzymes indicate that at least two different and opposing ubiquitination events occur during polyglutamine aggregation. The loss of ubiquitin localization after ubc-1, ubc-13, or uev-1 knockdown suggests that these enzymes might be directly involved in ubiquitination of aggregating proteins.
In the cell, misfolded proteins are usually degraded. In some cases, when a misfolded protein is not efficiently removed from the cell, protein aggregation will occur. Aggregation occurs in neurodegenerative diseases such as Huntington's disease, Parkinson's disease, Alzheimers disease, amyotrophic lateral sclerosis (ALS), spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy, Prion diseases, spinocerebellar ataxias and others . In these diseases, aggregation largely correlates with cell dysfunction and cell death. The role that protein aggregation plays in the damage that occurs in neurodegenerative diseases is not completely clear. It appears that aggregation itself is harmful because the expression of aggregating peptides in transgenic mice can lead to neurodegenerative symptoms [2, 3]. However, additional evidence suggests that the aggregates themselves may be protective and that the soluble mutant protein fragments might be toxic [4, 5]. Several models have been proposed to explain the toxicity of aggregating proteins including impairments of transcription , protein degradation , protein trafficking , or protein folding .
The precise molecular pathway leading to aggregation is not well-known. Structural studies on aggregating polyglutamine proteins indicate that they adopt a β-sheet crystalline conformation characteristic of amyloid fibrils . Aggregation is typically considered to be an unfavorable activity for proteins and, indeed, there are mechanisms to prevent such aggregation. Molecular chaperones seem to prevent the formation of protein aggregates in the cell. Overexpression of chaperone proteins can lead to a decrease in the amount of aggregation . Polyglutamine models in the nematode, C. elegans, have indicated that expression of polyglutamine proteins is toxic and that chaperones as well as other proteins can serve to ameliorate that toxicity [12–15].
Early in the study of the protein aggregation phenomenon, it was observed that the small protein, ubiquitin, becomes concentrated at sites of aggregation . Since the initial discovery of ubiquitin in aggregates, it has been found in almost every case of aggregation-related neurodegenerative diseases [1, 17]. The nature of the ubiquitin present in the aggregates is unknown. It is generally presumed that ubiquitin is conjugated onto substrate proteins such as the aggregating protein itself or other proteins that colocalize to aggregates. In fact, there is some evidence that aggregating proteins are ubiquitinated [18, 19]. However, it is also possible that ubiquitin is present in its monomeric state, or coupled with enzymes of the ubiquitination pathway such as E1, E2, or E3 enzymes.
Proteasomes also localize to protein aggregates in the aforementioned diseases . Although it has been shown numerous times that ubiquitin and proteasomes colocalize to aggregates, the role that either plays in aggregation has not been elucidated. Since aggregated proteins are somewhat resistant to proteolysis [21, 22], it is possible that the aggregating proteins are tagged for degradation by ubiquitin, but not degraded, thus concentrating ubiquitin and proteasomes at sites of aggregation. Ubiquitin has many functions in the cell aside from tagging proteins for degradation. It can serve as a modulator of protein trafficking, DNA repair, transcription, etc. . Thus, the role of ubiquitination in protein aggregation need not be restricted to the degradative pathway.
Ubiquitin becomes linked to other proteins via an isopeptide bond between the C-terminal glycine of ubiquitin and a lysine side chain on the modified protein. Ubiquitination occurs via a conserved, three-step process involving the E1, E2 and E3 components of the pathway [24, 25]. The E1 ubiquitin activating enzyme first interacts with ubiquitin using an ATP-dependent mechanism to form a thiolester linkage between a cysteine residue on the E1 and the C-terminal glycine of ubiquitin. Ubiquitin is subsequently transferred from the E1 to a cysteine residue on the E2 ubiquitin conjugating enzyme (Ubc). Next, the E3 ubiquitin ligases become involved in the process. The E3s are a diverse class of proteins and they can function in the pathway in one of two ways. Some E3s, such as the HECT domain E3s, form a thiolester linkage with ubiquitin and then subsequently transfer ubiquitin onto the target protein. In contrast, the more abundant E3s, such as the RING domain E3s, do not act as true enzymes, but rather function as a scaffold, interacting with both the target protein and the Ubc, thus allowing transfer of ubiquitin from the Ubc onto the target protein. Ubiquitination can occur in the form of monoubiquitination (addition of a single ubiquitin) or polyubiquitination (addition of a chain of ubiquitins).
In order to investigate the role of ubiquitination in protein aggregation, we have used a transgenic nematode system as well as cultured human cells. The transgenic worm strain expresses GFP fused to a stretch of 82 glutamines (Q82:GFP). This strain of nematodes has large fluorescent aggregates in the body wall muscles of larvae and adults . A similar strain was used to screen for genes that affect the timing of aggregate accumulation . That screen identified the ubiquitin activating enzyme (uba-1) as an important polyglutamine regulator. Our results show that perturbation of ubiquitin conjugating enzymes via RNAi has a significant effect on aggregate size and number. Specifically, in nematodes, RNAi of the ubc-2 or ubc-22 genes reduces the number but increases the size of aggregates. RNAi of ubc-1 or ubiquitin itself increases the number but decreases the size of aggregates. In HEK293 cultured cells, shRNA knockdown of the human homologs of these Ubc genes shows similar effects on aggregates, indicating a conserved function for these enzymes. Because there are two different phenoptyes observed upon knockdown of different Ubc enzymes, this suggests that there are at least two separate ubiquitination events that occur in the formation or metabolism of aggregates.
The RNAi technique was used to knockdown ubiquitination enzymes in cells expressing polyglutamine proteins. The nematode, C. elegans, has 22 different Ubc's and 4 Uev's (u biquitin conjugating e nzyme v ariants) encoded in its genome . Using available cDNA clones for eleven of the Ubc's and two of the Uev's, we performed an RNAi screen of these enzymes.
A worm model for polyglutamine protein aggregation was developed by Saytal et al.  and later converted into an integrated strain as described . This strain of worms expresses GFP that has been fused to 82 glutamines. The unc-54 promoter is used to drive expression of this fusion protein, resulting in expression in body wall muscle cells of the worm. We refer to this strain of worms as the Q82:GFP strain.
RNAi of most Ubc's did not cause a discernable difference in aggregate size or number, however, Figure 1 shows that knockdown of ubc-2 and ubc-22 resulted in a significant reduction in the number of aggregates per worm and an increase in the average size of aggregates. Knockdown of ubc-1, ubc-13, uev-1, and ubq-1 resulted in a reduction in the size of aggregates. RNAi of ubc-1 and ubq-1 also caused an increase in the number of aggregates. No other phenotypes in these worms were noticed besides a marked growth arrest and immobility in the ubq-1 and rpt-1 RNAi worms after 48 hours.
Because ubc-1 showed an opposite phenotype from ubc-2 and ubc-22, this suggests that there are at least two different ubiquitination events and that these different ubiquitinations may have separate effects on the formation or metabolism of the aggregates. RNAi of ubq-1, a gene encoding a polyprotein consisting of 11 ubiquitin peptides, was used to knockdown ubiquitin levels. Although the phenotype with ubq-1 RNAi is severe , it may not completely eliminate ubiquitin as there is a second gene, ubq-2, which also encodes ubiquitin. RNAi knockdown of ubq-1 showed a phenotype similar to that of ubc-1, suggesting that the UBC-1 mediated ubiquitination event is more prevalent or proceeds ubiquitination by UBC-2 or UBC-22.
Further evidence for the epistasis of ubc-1 came from combined RNAi experiments. When ubc-1 was knocked down in combination with ubc-2, or ubc-22, the ubc-1 phenotype was observed (Figure 1D). RT-PCR confirmed knockdown of both ubc-1 and ubc-2 in the combined RNA treatments (Figure 1E). The results from the combined RNAi experiments are consistent with a model where ubc-1 functions first in the cascade leading to ubiquitination of aggregating proteins.
There are several possible scenarios to explain how knockdown of Ubc's might affect the size and number of aggregates. First, the resulting Ubc deficiency could affect the total amount of Q82:GFP protein in the cell. Second, the solubility of Q82:GFP could be altered. Third, the composition or density of the aggregate could be affected.
Differences in aggregate size and number could also be explained by changes in the solubility of the polyglutamine proteins. This has been observed in several instances. For example, overexpression of chaperone proteins can increase the solubility of polyglutamine proteins and reduce aggregation [15, 29]. As a simple test for solubility, we analyzed the amount of soluble GFP in images of live worms, either RNAi treated or control (Figure 2B). Some soluble GFP is observed in Q82:GFP worms at this stage. However, there is no apparent change in the solubility upon any of the RNAi treatments. In contrast, examination of a strain containing a stretch of only 19 glutamines fused to GFP (Q19:GFP) clearly shows soluble GFP (diffuse green fluorescence).
RNAi of ubc-1, ubc-13 and uev-1 all resulted in smaller aggregates. Interestingly, these RNAi treatments also showed decreased localization of ubiquitin to aggregates. In addition, proteasome localization was abrogated in these knockdowns (Figure 3), consistent with the hypothesis that ubiquitin localization is a prerequisite for proteasome localization. Loss of ubiquitin from aggregates after knockdown of ubc-1, ubc-13 or uev-1 cannot be explained solely by the decrease in size since even smaller aggregates in control worms also stain positively with the ubiquitin and proteasome antibodies (Figure 3, top row).
Knockdown of ubc-2 or ubc-22, which both showed a dramatic increase in aggregate size, shows no effect on localization of ubiquitin or proteasome. Since ubiquitin localization is unaffected by RNAi of ubc- 2 or ubc-22, it is less likely that either of these Ubc's is involved in directly ubiquitinating aggregate proteins. ubc-1, ubc-13, and uev-1 are more likely candidates for enzymes involved in ubiquitinating aggregate proteins.
Our results in C. elegans suggest that ubiquitination plays an important role in the aggregation pathway. In order to investigate whether this might also be true in human cells, we performed shRNA experiments in HEK293 cells.
The worm genes showing the most dramatic phenotypes included ubc-1, ubc-2 and ubc-22. We searched for human orthologs of these Ubc's and identified two very close orthologs of ubc-1 and ubc-2: Ube2A and UbcH5b, respectively. The human and worm enzymes are extremely similar with Ube2A and UBC-1 showing 84% identity and UbcH5b and UBC-2 having 94% identity. There was no close ortholog for ubc-22, however E2-25K (also known as HIP2) was the closest human enzyme with 32% identity. E2-25K is a well studied Ubc enzyme and many activities have been attributed to it such as polyubiquitin chain synthesis, cyclization of ubiquitin chains, neddylation, NF-κB processing, and interaction with Huntingtin [30–33]. Although E2-25K and UBC-22 show a relatively low level of identity, they both contain a C-terminal UBA or ubiquitin associated domain as does Ubc1 of yeast.
After transfection, cells were examined for the size of aggregates as well as the number of aggregates per cell. Knockdown of Ube2A, the UBC-1 homolog, resulted in a decrease in the average size of aggregates (Figure 4C). In addition, more cells overall had aggregates and a greater percentage of cells had multiple aggregates (Figure 4D). These results are consistent with the effect of ubc-1 RNAi in worms. Therefore, the role that this enzyme plays in aggregate formation or metabolism is conserved.
Knockdown of UbcH5b, the UBC-2 homolog, resulted in a significant increase in the size of aggregates but did not affect the number of aggregates per cell (Figure 4C &4D). E2-25K (HIP2) is the Ubc that showed the lowest homology with its worm counterpart, UBC-22. E2-25K showed a modest affect on aggregate size and no affect on numbers of aggregates per cell. The RNAi phenotypes of UbcH5b and E2-25K suggest that any ubiquitination event(s) mediated by these enzymes somehow limits the size of aggregates.
Ube2A is a closely related human ortholog of the worm protein UBC-1. Although we do not know the subcellular localization of UBC-1 in worms, we have shown that UBC-1 affects ubiquitin localization to aggregates. Thus, it is not surprising to find that Ube2A localizes to aggregates. On the other hand, UBC-2, the worm ortholog of UbcH5b, did not affect ubiquitin localization. Therefore, it is curious that it would localize to aggregates. Perhaps it is involved in a minor ubiquitination event on aggregate proteins. Alternatively, UBC-2 might localize to aggregates due to the high concentration of ubiquitin and proteasomes that are present there.
It has long been known that the small protein modifier, ubiquitin, localizes to the large protein aggregates that form in several types of neurodegenerative diseases. We have investigated the role that ubiquitin plays in the formation or metabolism of these aggregates by performing knockdown of Ubc enzymes in the ubiquitination pathway. Our results indicate that ubiquitination plays an important role in polyglutamine protein aggregation.
Both ubc-2 and ubc- 22 had a similar phenotype: reduction of aggregate number and increase in aggregate size. This indicates that these two ubiquitinating enzymes may be involved in a common process that limits the size of aggregates. It is possible that ubiquitination by ubc-2 and ubc-22 is important for degrading aggregating proteins or for ridding the cell of aggregates that reach a certain size. However, removal of aggregates does not seem a likely mechanism for ubc-2 and ubc- 22, since their knockdown results in fewer aggregates than normal. Therefore, ubc-2 and ubc- 22 may be involved in limiting the coalescence of smaller aggregates into larger aggregates.
Since they have the same knockdown phenotype and the combined knockdown is not additive (Figure 1D), the two enzymes, UBC-2 and UBC-22, might participate in the same ubiquitination pathway or might function as a dimer. There is evidence from both in vitro and in vivo studies suggesting the existence of Ubc dimers and Ubc-Uev dimers [34, 35]. One interesting aspect of UBC-22 is that it has a non-canonical catalytic site with an awkwardly placed cysteine residue in a context lacking all consensus residues . Thus, it is possible that UBC-22 may not be catalytically active as a Ubc enzyme but rather partners with another functioning Ubc.
ubc-1, ubc-13, and uev-1 all showed a reduction in the size of aggregates. This reduction in size came without a reduction in the overall levels or a change in solubility of Q82:GFP protein. RNAi of ubc-1 had the most dramatic effect on size and also caused aggregates to be more numerous. UBC-1 could be involved in the process of smaller aggregates joining together into larger aggregates (Figure 6).
Since RNAi of ubc-1, ubc-13 and uev-1 all cause a reduction in aggregate size and loss of ubiquitin from aggregates, it is tempting to speculate that these enzymes might also function in the same pathway. In fact, it has been shown that the yeast homologs of these three enzymes function together in ubiquitination of PCNA. Rad6, the yeast homolog of ubc-1, is responsible for adding the initial ubiquitin molecule onto PCNA, and the ubiquitin chain is subsequently extended by the Ubc13/Uev1 dimer .
Knockdown of ubc-1, ubc-13 or uev-1 could cause aggregates to be smaller due to a decrease in overall bulk of the aggregate. Along with many other proteins, it is known that the proteasomes localize to aggregates and, thereby, could contribute to aggregate volume. Proteasome localization is disrupted after RNAi of ubc-1, ubc-13, or uev-1. Therefore, one possible scenario is that ubiquitination of Q82:GFP or some other protein attracts proteasomes to the aggregate. In the absence of that ubiquitination, proteasomes or other ubiquitin binding structures do not colocalize and thus the overall size of the aggregate is reduced.
We have used the nematode as a model for understanding the aggregation of polyglutamine proteins. The validity of this model was tested by examining the effects of Ubc RNAi in human cells expressing polyglutamine aggregates. Our results indicate that both worm cells and human cells deal with polyglutamine proteins using a conserved mechanism.
Using shRNA plasmids, we achieved knockdown of three human Ubc's that have homologs in our group of worm Ubc's with strong effects on aggregates. The human Ubc's with strong similarity to the worm enzymes showed phenotypes that mimicked the RNAi phenotype in worms. E2-25K, which has only weak identity to worm UBC-22, showed a less pronounced aggregate phenotype.
Using model systems, we have shown that knockdown of certain Ubc's can lead to changes in polyglutamine aggregates either in nematodes or human cells. However, the mechanism whereby ubiquitination affects protein aggregation remains unknown and could be either a direct or indirect affect of Ubc knockdown. The result that knockdown of ubc-1, ubc-13, and uev-1 reduce ubiquitin localization to aggregates favors a model where these enzymes participate directly in ubiquitinating components of the aggregate. It will be important to learn the targets for ubiquitination and to determine which Ubc's and ubiquitin ligases are involved in ubiquitinating those targets.
Worms were maintained at 20°C on nematode growth media with OP50 E. coli according to standard methods . The integrated Q82:GFP nematode strain is described elsewhere . The OP50 and HT115 bacterial strains as well as N2 worms were obtained from the Caenorhabditis Genetics Center.
The GATEWAY system (Invitrogen, Inc.) and the vector pL4440GTWY  were used to generate RNAi feeding plasmids . RNAi clones for ubc-1, ubc-2, ubc-7, ubc-8, ubc-13, ubc-14, ubc-16, ubc-20, ubc-22, ubc-24, uev-1, uev-2, ubq-1, and rpt-1 were made using recombinational cloning with pL4440GTWY and entry clones obtained from Mark Vidal and Open Biosystems, Inc. .
For aggregate expression in HEK293 cells, the Q81-YFP plasmid was generously provided by Dr James R. Burke (Duke University Medical Center Durham, NC). Expression Arrest™ human shRNA plasmids were from Open Biosystems. Expression Arrest™ contained either the non-silencing sequence which has no homology in mammals (control) or sequences specifically targeting Ube2A (1, RHS1764-9391619; 2, RHS1764-9690190), UbcH5b (1, RHS1764-9392787; 2, RHS1764-9685283), or E2-25K (1, RHS1764-9700185; 2, RHS1764-9100963).
RNAi was performed as previously described . Plasmids described above were transformed into HT115 E. coli. 35 mm NGM plates were supplemented with 1 mM isopropyl-β-thiogalactopyranoside (IPTG) and 100 mg/ml ampicillin and then seeded with 125 μl of saturated overnight culture. Q82:GFP nematode populations were synchronized by using a hypochlorite treatment to yield embryos. Embryos were placed on RNAi-seeded plates 2–4 hours after seeding. Worms were removed from plates after 24 or 48 hours for analysis. Control RNAi was performed using the pL4440 empty vector in HT115.
Nematodes were fixed in methanol onto polylysine-coated slides and mounted in Vectashield plus DAPI (4,6-diamidino-2-phenylindole). Aggresomes were counted by observation on a Nikon E600 microscope equipped with a QiCam digital camera (Q Imaging). A minimum of 10 worms were analyzed for each condition. Sizes of individual aggregates were determined using Image Pro software. At least 100 aggregates were sized for each RNAi condition. Soluble GFP was observed by anesthetizing nematodes with 25 mg/mL tetramisole (Sigma) in PBS.
Colocalization of ubiquitin and proteasome to aggregates was determined using mouse-anti-ubiquitin (1:200; P4D1 from Santa Cruz Biotechnology) and rabbit-anti-proteasome (1:200; ab2943 from Abcam). Nematodes were fixed with methanol onto polylysine-coated slides and incubated in primary antibody overnight followed by incubation with secondary antibody for 2 hours. Secondary antibodies were goat-anti-mouse Rhodamine and goat-anti-rabbit Rhodamine (Jackson ImmunoResearch) Worms were observed and analyzed using the microscopy tools mentioned above.
Cell culture reagents were purchased from Mediatech. HEK293 cells were transiently transfected using Arrest-In™ transfection reagent (Open Biosystems) following the manufacturer's protocol. Cell culture was done in DMEM with 10% FBS in an incubator with 5% CO2.
shRNA plasmids were isolated using a Qiagen kit and verified using restriction digests. Transfections were done in 6 well plates. For each well, 2 μg of shRNA plasmid and 100 ng of Q81:YFP in 50 μl of serum free DMEM was added to 50 μl of diluted Arrest-In™ and left at room temperature for 15 min. The transfection mixture was added drop wise to the wells and incubated at 37°C; 5% CO2. Media was changed 1 day following transfection. Cells were analyzed 72 hrs after transfection.
Images were taken of cells containing fluorescent aggregates 72 hrs after transfection with shRNA plasmids. Each experiment was repeated three times and each time 150 transfected cells were examined. The number of aggregates per cell was counted, and area of each aggregate was measured using SPOT software (Diagnostics Instruments). Area of aggregates was converted to μm2 by calibrating with a micrometer (1 μm was equivalent to 39.6 pixels).
For localization of Ubc proteins in aggregate-containing cells, HEK293 cells were cultured in 24 well plates and transfected with 100 ng of Q81:YFP in each well. Cells were incubated for 48 hrs, then trypsinized and transferred to 4-chambered slides (NUNC). After another 24 hrs, cells were washed once with PBS and fixed with 4% paraformaldehyde (in PBS) at 4°C for 30 min. Cells were checked for fixation under a light microscope. After fixation, cells were washed three times with Tris buffered saline (TBS; 50 mM Tris, 150 mM NaCl pH 7.6) followed by blocking (1% BSA, 0.3% Triton-X-100 in TBS) for 1 hr at room temperature. Primary antibody (rabbit-anti-E2-25K from Boston Biochem 1: 200 or goat-anti-Ube2A polyclonal 1: 100 or goat anti-Ubch5B polyclonal 1:100 both from Santa Cruz Biotechnology) was added in 1% BSA, 0.3% Triton-X-100 and incubated overnight at 4°C. Slides were then washed three times with TBS followed by incubation with secondary antibody (goat-anti-rabbit Rhodamine from Jackson ImmunoResearch or rabbit-anti-goat Rhodamine from Open Biosystems) in 1% BSA, 0.3% Triton-X-100 and incubated for 6 hrs at 4°C in the dark. Cells were washed three times with TBS. Chambers were removed from the slides very carefully until no gum was left on the slide. Prolong Gold Antifade reagent with DAPI (Molecular Probes) was added and was allowed to cure overnight at 4°C in dark. Cells were examined using a Leica DMIRB inverted microscope equipped with a SPOT RT slider color digital camera. Images were obtained with blue, green, red fluorescence filters. Images were processed by C IMAGING software (SIMPLE PCI Inc.).
Worms were grown on RNAi plates for 48 hours, collected by centrifugation, washed 5 times with PBS, and frozen at -80°C. Frozen pellets were ground using a mortar and pestle in liquid N2. RNA extractions were performed using the QiaShredder and RNeasy miniprep kits (Qiagen). cDNA was synthesized from the RNA samples with the Transcriptor First Strand cDNA kit (Roche) using 10 μl of RNA as template. PCR reactions used 2 μl of cDNA and the following primers: UBC1F CAAATAAACCGCCAACCGTCAA, UBC1R TCTCATATTCCCGTCGATTTTCTT, UBC2F ACTTCCCAACAGACTATCCATTCA, UBC2R AGCGTACTTTTGCGTCCATTCTCT, ACT1F CCGCCGGAATCCACGAGACT, ACT1R GTGGAGAGGGAAGCGAGGATAGAT.
Worms were grown on RNAi plates for 48 hours, collected by centrifugation, washed with sterile water, and suspended in 1× protein sample buffer with BME. Samples were heated at 100°C for 5 minutes, resolved on 10% SDS-polyacrylamide gels, transferred to PVDF membranes, and incubated overnight with mouse anti-GFP antibody (1:200; Santa Cruz Biotechnology) at 4°C and 1 hour at room temperature with secondary antibody (1:10,000, Pierce) Blots were reprobed with anti-actin antibody (1:500; C4 from Abcam) Bound antibody was detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce). Densitometric measurements were performed using Image J software.
Cells were collected from plates following trypsinization, then washed with 1× PBS and suspended in PBS. Lysis was done by boiling in loading buffer (50 mM Tris-HCl, pH 6.8 10% SDS, 0.1% bromophenol blue, 10% glycerol) followed by 1 min sonication. Lysates were centrifuged at 14,000 rpm for 10 min at 4°C. Samples were electrophoresed through 10% SDS-polyacrylamide gels and transferred to PVDF membranes. Membranes were probed overnight at 4°C with using the same primary antibodies used for immunofluorescence (dilutions: anti-E2-25K 1:1000, anti-Ube2A 1:200, anti- UbcH5b 1:200, anti-tubulin from the Developmental Studies Hybridoma Bank at the University of Iowa 1:1000). The secondary antibody (goat-anti-mouse HRP or rabbit-anti-goat HRP; Pierce) used diluted 1:10,000 and bound antibody was detected with SuperSignal West Pico Chemiluminescent Substrate.
We thank Marc Vidal and Open Biosystems for providing ORF clones used in this research. Also, we thank Enrique Sosa and David Cao for help with microsocopy and sizing of aggregates. We are especially grateful to R. Morimoto, J. Burke and A. Fire for generously contributing plasmids used in this study. Some nematode and bacterial strains were provided by the Caenorhabditis Genetics Center at the University of Minnesota which is funded by the NIH National Center for Research Resources (NCRR). This work was supported by a grant from the NIH to L.B. (R15 GM065444-02).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.